All News
Filter News
Found 808,615 articles
-
Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting
6/9/2021
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that an abstract featuring new preclinical data for its IRAKIMiD degrader KT-413 has been selected for oral presentation at the 16th Annual International Conference.
-
Roche's Accu-Chek Inform II Hospital Blood Glucose System now approved by Health Canada for Intensive Care Use
6/9/2021
The Accu-Chek® Inform II system (ACI II) supports Point of Care coordinators, physicians, nurses, IT experts and infection control managers to optimize their complex workflow.
-
Sapience Therapeutics to Present at BIO Digital 2021
6/9/2021
Sapience Therapeutics, Inc., announced today that the company will present and participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.
-
ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes
6/9/2021
ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total Series D financing to more than $115 million.
-
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
6/9/2021
WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, "LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in development and manufacturing of antibody-drug conjugates (ADCs).
-
Predictive Health Diagnostics Company Announces Strong Momentum with 120,000th PULS Cardiac Test™ Order
6/9/2021
Predictive Health Diagnostics Company, Inc. ("PHDC" or "the Company"), today announced a new milestone with placement of the 120,000th order of the PULS Cardiac Test™
-
New next generation device improves the well-being of people affected by swallowing disorders and dysphagia
6/9/2021
The Mobili-T® system was brought to market by a health company, True Angle, an award-winning startup that just raised an oversubscribed $1.64M investment round backed by investment firms such as Accelerate Fund, Thin Air Labs, The 51 and others.
-
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
6/9/2021
U.S. FDA Approves PREVNAR 20 ™ , Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older.
-
nanoMesh™ LLC (a subsidiary of Exogenesis Corporation) Announces Secondary Endpoint Achieved in nanoMesh™ Pathogen Inhibiting Protein (PIP) Uptake Studies
6/9/2021
nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the secondary endpoints for the nanoMesh™ Pathogen Inhibiting Protein (PIP) uptake studies.
-
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
6/9/2021
Synaptogenix, Inc. today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial f Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease.
-
Personal Genome Diagnostics Appoints Brent Dial as Chief Financial Officer
6/9/2021
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Brent Dial, MBA, as Chief Financial Officer.
-
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
6/9/2021
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Sue-Jean Lin has been appointed to the Arcutis Board of Directors
-
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
6/9/2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021.
-
iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
6/9/2021
iTolerance, Inc today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist.
-
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
6/9/2021
Celcuity Inc. today announced the addition of two new senior executives. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development and Jill Krause joined as VP of Clinical Operations.
-
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design StudyInterim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
6/9/2021
MediWound Ltd. (Nasdaq: MDWD), today announced that the enrollment target of patients for an interim assessment of its EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been achieved, and interim assessment is expected by the end of July 2021.
-
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
6/9/2021
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week.
-
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
6/9/2021
Lysogene today announced dosing of the first patient, at Royal Manchester Children’s Hospital, part of Manchester University NHS Foundation Trust, in the global adaptative-design clinical trial with LYS-GM101.
-
Q-State Biosciences Announces Presentation at the Upcoming Antiepileptic Drug & Device Trials XVI Symposium
6/9/2021
Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced the company will present at the upcoming 2021 Antiepileptic Drug & Device Trials (AEDD) XVI Symposium to be held June 16-18.
-
Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States
6/9/2021
Onxeo S.A . today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA.